Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2019; 19(4):241-243,320
DOI: 10.5428/pcar20190401
Research advances in targeted therapeutic drugs of pancreatic cancer
1. SHI Yamin1(1.Teaching and Research Section of Pharmaceutics,School of Pharmacy,Fujian University of Traditional Chinese Medicine,Fuzhou 350108,China 1576671627@qq.com)
2. LU Yue2(2.Shanghai Weier Laboratory,Shanghai 201712,China )
3. WU Xin2(2.Shanghai Weier Laboratory,Shanghai 201712,China )
4. CHEN Jianming1(1.Teaching and Research Section of Pharmaceutics,School of Pharmacy,Fujian University of Traditional Chinese Medicine,Fuzhou 350108,China yjcjm@163.com)
ABSTRACT  Pancreatic cancer is a malignant tumor in the digestive system with almost the same rate of morbidity and mortality.Present treatment methods include surgical resection,radiotherapy and chemotherapy but with certain limitations.Compared with the traditional treatment methods,targeted drugs have the advantages of accurately reaching tumor cells or tissues and inhibiting or killing cancer cells.In this article,the research advances of targeted therapeutic drugs of pancreatic cancer in recent years were reviewed from three aspects of vascular-targeted drugs,cell-targeted drugs and immune-targeted drugs.
Welcome to PCAR! You are the number 105 reader of this article!
Please cite this article as:
SHI Yamin1,LU Yue2,WU Xin2,CHEN Jianming1,. Research advances in targeted therapeutic drugs of pancreatic cancer[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2019; 19(4): 241-243,320.
References:
1. LI Huichao,WANG Ning,ZHENG Rongshou,et al.An analysis of incidence and mortality of pancreas cancer in China,2010[J].China Cancer,2015,24(3):163-169.In Chinese with English abstract.
2. BAI Yannan,YAN Maolin.Interpretation of surgical related parts of pancreatic cancer comprehensive diagnosis and treatment guide (2018 version)[J].Chin J Bases Clin Gen Surg,2018,25(6):669-672.In Chinese.
3. ZHANG Dongmei,QING Chen.Vascular endothelial growth factor family and tumor angiogenesis[J].Med Recapitulate,2017,23(3):417-420,427.In Chinese with English abstract.
4. Itatani Y,Kawada K,Yamamoto T,et al.Resistance to anti-angiogenic therapy in cancer-alterations to anti-VEGF pathway[J].Int J Mol Sci,2018,19(4):1232.
5. Tai C J,Huang M T,Wu C H,et al.Combination of two targeted medications (bevacizumab plus cetuximab) improve the therapeutic response of pancreatic carcinoma[J].Medicine(Baltimore),2016,95(15):e3259.
6. Tai C J,Wang H,Wang C K,et al.Bevacizumab and cetuximab with conventional chemotherapy reduced pancreatic tumor weight in mouse pancreatic cancer xenografts[J].Clin Exp Med,2017,17(2):141-150.
7. Noorani M,Azarpira N,Karimian K,et al.Erlotinib-loaded albumin nanoparticles:a novel injectable form of erlotinib and its in vivo efficacy against pancreatic adenocarcinoma ASPC-1 and PANC-1 cell lines[J].Int J Pharm,2017,531(1):299-305.
8. JIA Congwei,SUN Yang,ZHANG Tingting,et al.Effects of miR-125a-5p on cell proliferation,apoptosis and cell cycle of pancreatic cancer cells[J].Acta Acad Med Sin,2016,38(4):415-421.In Chinese with English abstract.
9. LI Yiqing,ZHU Haifeng,WANG Lu.Clinical effect and the safety of gemcitabine combined with albumin bound paclitaxel in the treatment of pancreatic cancer[J].Chin J Clin Ration Drug Use,2017,10(5C):33-34.In Chinese with English abstract.
10. Von Hoff D D,Ervin T,Arena F P,et al.Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine[J].N Engl J Med,2013,369(18):1691-1703.
11. Horiuchi T,Uwagawa T,Shirai Y,et al.New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer[J].J Surg Res,2016,206(1):1-8.
12. ZHU Lingxi,AN Huazhang.Regulation mechanism of PD-L1 expression and its effect on antitumor immune responses[J].Chin J Cancer Biother,2017,24(4):335-340.In Chinese with English abstract.
13. Foley K,Kim V,Jaffee E,et al.Current progress in immunotherapy for pancreatic cancer[J].Cancer Lett,2016,381(1):244-251.
14. Patnaik A,Kang S P,Rasco D,et al.Phase Ⅰ study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors[J].Clin Cancer Res,2015,21(19):4286-4293.
15. Long G V,Atkinson V,Lo S,et al.Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases:a multicentre randomised phase 2 study[J].Lancet Oncol,2018,19(5):672-681.
16. Royal R E,Levy C,Turner K,et al.Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma[J].J Immunother,2010,33(8):828-833.
17. Mass-Vall s D,Jauset T,Serrano E,et al.Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma[J].Cancer Res,2015,75(8):1675-1681.
18. Allen E,Jabouille A,Rivera L B,et al.Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation[J].Sci Transl Med,2017,9(385):eaak9679.
19. YE Zhenlong,QIAN Qiming,JIN Huajun,et al.Cancer vaccine:learning lessons from immune checkpoint inhibitors[J].J Cancer,2018,9(2):263-268.
20. Yokoyama S,Kitamoto S,Higashi M,et al.Diagnosis of pancreatic neoplasms using a novel method of DNA methylation analysis of mucin expression in pancreatic juice[J].PLoS One,2014,9(4):e93760.
21. Shindo Y,Hazama S,Maeda Y,et al.Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer[J].J Transl Med,2014,12:175.
22. Middleton G,Silcocks P,Cox T,et al.Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac):an open-label,randomised,phase 3 trial[J].Lancet Oncol,2014,15(8):829-840.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口